从药物重新定位到基于结构的药物设计方法来应对急性淋巴细胞白血病
Magali Saez-Ayala1, Laurent Hoffer2,3, Sébastien Abel2
1Centre de Recherche en Cancérologie de Marseille (CRCM), CNRS, INSERM, Aix-Marseille Univ, Institut Paoli-Calmettes, Marseille, France. magali.saez-ayala@inserm.fr.
Nature communications
|May 29, 2023
概括
研究人员使用计算设计开发出一种强大的脱氧化丁激酶抑制剂,OR0642. 这种新药物与de novo路径抑制剂相结合,在白血病小鼠模型中显著提高了生存率.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 癌细胞需要脱氧核酸来增殖,利用新生和救援途径.
- 脱氧丁酶是救援途径中的关键酶,是抗癌疗法的验证标.
研究的目的:
- 用一种代的,多学科的方法开发一种强大的脱氧基丁激酶抑制剂.
- 评估化合物在白血病联合治疗中的疗效.
主要方法:
- 采用计算设计和实验验证,用于代药物开发.
- 通过化学修饰评估化合物的功效和活性.
- 在白血病异种移植模型中测试了化合物OR0642与de novo路径抑制剂的组合.
主要成果:
- 开发了OR0642,它是一种除氧化丁激酶抑制剂,比masitinib强1000倍以上.
- 在人类T细胞急性淋巴细胞白血病异种移植模型中,OR0642与de novo路径抑制剂相结合,使生存率翻了一番.
结论:
- 代计算和实验方法成功加速了药物开发.
- 脱氧丁激酶和de novo途径的联合抑制显示出白血病的显著治疗潜力.
相关概念视频
Structure-Activity Relationships and Drug Design
801
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
801
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K


